Document Classification

Section Type: RESULTS

Text: Atomoxetine was superior to placebo on CAARS : Investigator-Rated : Screening Version (atomoxetine [least-squares mean SE, -13. 6 0. 8] vs placebo [-9. 3 0. 8], 95 % confidence interval [-6. 35 to -2. 37], P < 0. 001), Clinical Global Impression-ADHD-Severity (atomoxetine [-1. 1 0. 1] vs placebo [-0. 7 0. 1], 95 % confidence interval [-0. 63 to -0. 24], P < 0. 001), and CAARS Self-Report (atomoxetine [-11. 9 0. 8] vs placebo [-7. 8 0. 7], 95 % confidence interval [-5. 94 to -2. 15], P < 0. 001) but not on Patient Global Impression-Improvement.